Similarly, a meta-analysis in NSCLC discovered SFRP1’s transcriptional silencing as a consequence from promoter methylation, revealing a promising application of epigenetic therapy in NSCLC [41]. The gene discussed is SFRP1; the disease is non-small cell lung carcinoma.